anidulafungin and voriconazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Aspergillosis
Conditions
Aspergillosis, Candidemia
Trial Timeline
Sep 1, 2008 → Oct 1, 2008
NCT ID
NCT00940017About anidulafungin and voriconazole
anidulafungin and voriconazole is a approved stage product being developed by Pfizer for Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00940017. Target conditions include Aspergillosis, Candidemia.
What happened to similar drugs?
7 of 15 similar drugs in Aspergillosis were approved
Approved (7) Terminated (6) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00940017 | Approved | Completed |
Competing Products
20 competing products in Aspergillosis